Previous 10 | Next 10 |
2023-09-25 18:19:45 ET More on Madrigal Pharmaceuticals Madrigal's Resmetirom Nears Commercialization Despite Market Concerns Madrigal Pharmaceuticals: The NASH Market Is No Longer Guaranteed Madrigal: With Successful NASH Study, Possible Accelerated Approval Is Next...
2023-09-25 17:15:50 ET Gainers: Pliant Therapeutics ( NASDAQ: PLRX ) +8% . ARS Pharmaceuticals ( SPRY ) +6% . Amylyx Pharmaceuticals ( AMLX ) +4% . Seres Therapeutics ( MCRB ) +2% . Pulmonx Corporation ( LUNG ) +2% . Lo...
2023-09-20 07:00:00 ET Over the past year or more, the market has soured on unprofitable clinical-stage biotech companies, an understandable development. Investors prefer to put their money in stable and established corporations that generate consistent earnings and cash flow when the going...
2023-09-19 04:37:07 ET Summary John Paulson's 13F portfolio value decreased by 15% to $1.02B this quarter. The top five positions in Paulson's portfolio are Bausch Health, BrightSphere Investment Group, Perpetua Resources, NovaGold, and Madrigal Pharma. Paulson made new stakes...
CONSHOHOCKEN, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it made an inducement grant to Bill Sibold on September 11, 2023...
2023-09-14 08:15:00 ET Summary Galecto Biotech's stock has plummeted 75% due to increased rates of adverse events in its idiopathic pulmonary fibrosis (IPF) trial. Galecto's synthetic, small molecule approach to galectin-3 inhibition may be causing poor tolerability and negative c...
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is one of today's top gainers. The company's shares are currently up 6.53% on the day to $188.42. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates...
2023-09-13 09:58:15 ET More on Madrigal Seeking Alpha’s Quant Rating on Madrigal Pharmaceuticals Historical earnings data for Madrigal Pharmaceuticals Financial information for Madrigal Pharmaceuticals Madrigal's Resmetirom Nears Commercialization Desp...
CONSHOHOCKEN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has accepted for rev...
2023-09-11 07:28:46 ET More on Madrigal Pharmaceuticals Seeking Alpha’s Quant Rating on Madrigal Pharmaceuticals Historical earnings data for Madrigal Pharmaceuticals Financial information for Madrigal Pharmaceuticals Madrigal's Resmetirom Nears Commer...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...